PHILOGEN SPA (PHIL.MI) Stock Fundamental Analysis
Europe - BIT:PHIL - IT0005373789 - Common Stock
24 EUR
-0.2 (-0.83%)
We assign a fundamental rating of 7 out of 10 to PHIL. PHIL was compared to 74 industry peers in the Biotechnology industry. PHIL has an excellent financial health rating, but there are some minor concerns on its profitability. PHIL is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, PHIL could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
PHIL had positive earnings in the past year.
PHIL had a positive operating cash flow in the past year.
PHIL had negative earnings in 4 of the past 5 years.
In the past 5 years PHIL reported 4 times negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 28.81%, PHIL belongs to the best of the industry, outperforming 94.59% of the companies in the same industry.
The Return On Equity of PHIL (36.49%) is better than 95.95% of its industry peers.
PHIL has a Return On Invested Capital of 21.08%. This is amongst the best in the industry. PHIL outperforms 95.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.81% | ||
| ROE | 36.49% | ||
| ROIC | 21.08% |
ROA(3y)5.82%
ROA(5y)-1.99%
ROE(3y)6.79%
ROE(5y)-3.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHIL has a better Profit Margin (58.33%) than 95.95% of its industry peers.
PHIL's Profit Margin has improved in the last couple of years.
PHIL's Operating Margin of 49.47% is amongst the best of the industry. PHIL outperforms 97.30% of its industry peers.
Looking at the Gross Margin, with a value of 74.04%, PHIL is in the better half of the industry, outperforming 67.57% of the companies in the same industry.
PHIL's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 49.47% | ||
| PM (TTM) | 58.33% | ||
| GM | 74.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y40.66%
GM growth 3YN/A
GM growth 5Y18.26%
2. Health
2.1 Basic Checks
PHIL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for PHIL remains at a similar level compared to 1 year ago.
PHIL has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, PHIL has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 14.98 indicates that PHIL is not in any danger for bankruptcy at the moment.
PHIL has a Altman-Z score of 14.98. This is amongst the best in the industry. PHIL outperforms 91.89% of its industry peers.
PHIL has a debt to FCF ratio of 0.31. This is a very positive value and a sign of high solvency as it would only need 0.31 years to pay back of all of its debts.
The Debt to FCF ratio of PHIL (0.31) is better than 90.54% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that PHIL is not too dependend on debt financing.
PHIL has a better Debt to Equity ratio (0.08) than 62.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 0.31 | ||
| Altman-Z | 14.98 |
ROIC/WACC2.6
WACC8.12%
2.3 Liquidity
PHIL has a Current Ratio of 5.73. This indicates that PHIL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.73, PHIL belongs to the top of the industry, outperforming 83.78% of the companies in the same industry.
A Quick Ratio of 5.52 indicates that PHIL has no problem at all paying its short term obligations.
The Quick ratio of PHIL (5.52) is better than 85.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.73 | ||
| Quick Ratio | 5.52 |
3. Growth
3.1 Past
PHIL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 255.77%, which is quite impressive.
The Earnings Per Share has been growing by 100.72% on average over the past years. This is a very strong growth
The Revenue has grown by 3346.54% in the past year. This is a very strong growth!
PHIL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 42.46% yearly.
EPS 1Y (TTM)255.77%
EPS 3YN/A
EPS 5Y100.72%
EPS Q2Q%3.48%
Revenue 1Y (TTM)3346.54%
Revenue growth 3Y209.5%
Revenue growth 5Y42.46%
Sales Q2Q%606.29%
3.2 Future
PHIL is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.40% yearly.
PHIL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.55% yearly.
EPS Next Y14.99%
EPS Next 2Y-51.63%
EPS Next 3Y-72.12%
EPS Next 5Y-3.4%
Revenue Next Year112.03%
Revenue Next 2Y-21.13%
Revenue Next 3Y-34.37%
Revenue Next 5Y22.55%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 21.05 indicates a rather expensive valuation of PHIL.
Based on the Price/Earnings ratio, PHIL is valued cheaper than 83.78% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.35, PHIL is valued a bit cheaper.
With a Price/Forward Earnings ratio of 17.43, PHIL is valued on the expensive side.
PHIL's Price/Forward Earnings ratio is rather cheap when compared to the industry. PHIL is cheaper than 90.54% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 33.72. PHIL is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.05 | ||
| Fwd PE | 17.43 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PHIL is valued cheaper than 82.43% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHIL indicates a rather cheap valuation: PHIL is cheaper than 87.84% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.06 | ||
| EV/EBITDA | 12.33 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PHIL has a very decent profitability rating, which may justify a higher PE ratio.
PHIL's earnings are expected to decrease with -72.12% in the coming years. This may justify a cheaper valuation.
PEG (NY)1.4
PEG (5Y)0.21
EPS Next 2Y-51.63%
EPS Next 3Y-72.12%
5. Dividend
5.1 Amount
No dividends for PHIL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:PHIL (11/11/2025, 5:06:13 PM)
24
-0.2 (-0.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners8.18%
Inst Owner ChangeN/A
Ins Owners34.46%
Ins Owner ChangeN/A
Market Cap701.76M
Revenue(TTM)78.72M
Net Income(TTM)45.91M
Analysts82.5
Price Target28.56 (19%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.67%
PT rev (3m)-6.67%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-26.32%
EPS NY rev (3m)996.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-25.35%
Revenue NY rev (3m)-24.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.05 | ||
| Fwd PE | 17.43 | ||
| P/S | 8.91 | ||
| P/FCF | 19.06 | ||
| P/OCF | 17.74 | ||
| P/B | 5.58 | ||
| P/tB | 5.63 | ||
| EV/EBITDA | 12.33 |
EPS(TTM)1.14
EY4.75%
EPS(NY)1.38
Fwd EY5.74%
FCF(TTM)1.26
FCFY5.25%
OCF(TTM)1.35
OCFY5.64%
SpS2.69
BVpS4.3
TBVpS4.26
PEG (NY)1.4
PEG (5Y)0.21
Graham Number10.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.81% | ||
| ROE | 36.49% | ||
| ROCE | 28.1% | ||
| ROIC | 21.08% | ||
| ROICexc | 75.73% | ||
| ROICexgc | 78.23% | ||
| OM | 49.47% | ||
| PM (TTM) | 58.33% | ||
| GM | 74.04% | ||
| FCFM | 46.77% |
ROA(3y)5.82%
ROA(5y)-1.99%
ROE(3y)6.79%
ROE(5y)-3.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y40.66%
GM growth 3YN/A
GM growth 5Y18.26%
F-Score8
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | 0.31 | ||
| Debt/EBITDA | 0.24 | ||
| Cap/Depr | 67.4% | ||
| Cap/Sales | 3.47% | ||
| Interest Coverage | 78.84 | ||
| Cash Conversion | 91.98% | ||
| Profit Quality | 80.19% | ||
| Current Ratio | 5.73 | ||
| Quick Ratio | 5.52 | ||
| Altman-Z | 14.98 |
F-Score8
WACC8.12%
ROIC/WACC2.6
Cap/Depr(3y)124.83%
Cap/Depr(5y)196.93%
Cap/Sales(3y)15.46%
Cap/Sales(5y)79.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)255.77%
EPS 3YN/A
EPS 5Y100.72%
EPS Q2Q%3.48%
EPS Next Y14.99%
EPS Next 2Y-51.63%
EPS Next 3Y-72.12%
EPS Next 5Y-3.4%
Revenue 1Y (TTM)3346.54%
Revenue growth 3Y209.5%
Revenue growth 5Y42.46%
Sales Q2Q%606.29%
Revenue Next Year112.03%
Revenue Next 2Y-21.13%
Revenue Next 3Y-34.37%
Revenue Next 5Y22.55%
EBIT growth 1Y218.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.38%
EBIT Next 3Y-70.2%
EBIT Next 5YN/A
FCF growth 1Y1324.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6769.31%
OCF growth 3YN/A
OCF growth 5Y135.99%
PHILOGEN SPA / PHIL.MI FAQ
What is the ChartMill fundamental rating of PHILOGEN SPA (PHIL.MI) stock?
ChartMill assigns a fundamental rating of 7 / 10 to PHIL.MI.
What is the valuation status of PHILOGEN SPA (PHIL.MI) stock?
ChartMill assigns a valuation rating of 6 / 10 to PHILOGEN SPA (PHIL.MI). This can be considered as Fairly Valued.
Can you provide the profitability details for PHILOGEN SPA?
PHILOGEN SPA (PHIL.MI) has a profitability rating of 6 / 10.
Can you provide the financial health for PHIL stock?
The financial health rating of PHILOGEN SPA (PHIL.MI) is 9 / 10.
Can you provide the expected EPS growth for PHIL stock?
The Earnings per Share (EPS) of PHILOGEN SPA (PHIL.MI) is expected to grow by 14.99% in the next year.